Patents Assigned to SynPhaGen LLC
  • Treatment delivery system and method
    Publication number: 20230285508
    Abstract: Compositions for a phage particle are disclosed. The phage particle is non-replicating and includes at least one heterologous nucleic acid sequence that is capable of being expressed in a target bacteria. The expressed heterologous nucleic acid sequence is non-lethal to the target bacteria.
    Type: Application
    Filed: May 17, 2023
    Publication date: September 14, 2023
    Applicant: SynPhaGen LLC
    Inventors: Todd Bernard Parsley, Christian Furlan Freguia
  • Compositions for in vivo Expression of Therapeutic Sequences in the Microbiome
    Publication number: 20190315642
    Abstract: Compositions for a phage particle are disclosed. The phage particle is non-replicating and includes at least one heterologous nucleic acid sequence that is capable of being expressed in a target bacteria. The expressed heterologous nucleic acid sequence is non-lethal to the target bacteria.
    Type: Application
    Filed: June 3, 2019
    Publication date: October 17, 2019
    Applicant: SynPhaGen LLC
    Inventors: Todd Bernard Parsley, Christian Furlan Freguia
  • Compositions for in vivo expression of therapeutic sequences in the microbiome
    Patent number: 10351452
    Abstract: Compositions for a phage particle are disclosed. The phage particle is non-replicating and includes at least one heterologous nucleic acid sequence that is capable of being expressed in a target bacteria. The expressed heterologous nucleic acid sequence is non-lethal to the target bacteria.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: July 16, 2019
    Assignee: SynPhaGen LLC
    Inventors: Todd Bernard Parsley, Christian Furlan Freguia
  • Therapeutic phages and methods for delivery of nucleic acids for therapeutic uses
    Patent number: 9676641
    Abstract: Compositions for a phage particle are disclosed. The phage particle is non-replicating and includes at least one heterologous nucleic acid sequence that is capable of being expressed in a target bacteria. The expressed heterologous nucleic acid sequence is non-lethal to the target bacteria.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: June 13, 2017
    Assignee: SynPhaGen LLC
    Inventors: Todd Bernard Parsley, Christian Furlan Freguia
  • Compositions for in vivo Expression of Therapeutic Sequences in the Microbiome
    Publication number: 20160367701
    Abstract: Compositions for a phage particle are disclosed. The phage particle is non-replicating and includes at least one heterologous nucleic acid sequence that is capable of being expressed in a target bacteria. The expressed heterologous nucleic acid sequence is non-lethal to the target bacteria.
    Type: Application
    Filed: January 26, 2015
    Publication date: December 22, 2016
    Applicant: SynPhaGen LLC
    Inventors: Todd Bernard Parsley, Christian Furlan Freguia